India-based drugmaker Glenmark Pharmaceuticals have announced the inauguration of its first U.S manufacturing site in Monroe, North Carolina. The company anticipates the site will grow well beyond its current 168 employees. The Glenmark site is the largest pharmaceutical manufacturer in the Charlotte region.
"Our investment in Monroe is a key priority for Glenmark, and contributing to the surrounding community through high-quality job creation and educational investments is a critical success factor as we expand our global manufacturing operations into the U.S.," said Robert Matsuk, president, North America & Global API. "We have a commitment to long-term growth and expansion in North Carolina and are thankful for the mutual support from our community partners in helping realize those goals."
With more than 100,000 square feet, the Monroe, North Carolina facility is designed to manufacture a variety of fixed dose pharmaceutical formulations. Glenmark has invested more than $100 million into the facility with plans for further expansion in the coming years. At peak capacity, the site is anticipated to produce 300-400 million tablets and capsules, 20-25 million vials and pre-filled syringes and 25-30 million ampoules for inhaled formulations. Globally, Glenmark has 16 manufacturing facilities across four continents operating under Good Manufacturing Practices (GMP).
Read the full release